OM:CAMXPharmaceuticals
Is Camurus (OM:CAMX) Still Undervalued On Its FDA CAM2029 Milestone?
Camurus (OM:CAMX) is back in focus after the US Food and Drug Administration accepted the resubmitted New Drug Application for CAM2029 for acromegaly, with a new target review date now set.
See our latest analysis for Camurus.
Against this backdrop, Camurus shares have shown improving momentum, with a 13.16% 1 month share price return and 17.86% 3 month share price return, even though the 1 year total shareholder return is down 12.12% and the 5 year total shareholder return is up 244.48%.
If...